Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C

被引：0
|
作者：
Grohe, C. [1 ]
Wehler, T. [2 ]
Dechow, T. [3 ]
Henschke, S. [4 ]
Schuette, W. [5 ]
Dittrich, I [6 ]
Hammerschmidt, S. [7 ]
Mueller-Huesmann, H. [8 ]
Schumann, C. [9 ]
Krueger, S. [10 ]
Atz, J. [11 ]
Kaiser, R. [11 ]
机构：
[1] Evangel Lung Clin, Dept Pneumol, Berlin, Germany
[2] Evangel Krankenhaus Hamm GmbH, Hamm, Germany
[3] Oncol Haematol Grp Practice, Ravensburg, Germany
[4] Saarland Univ Hosp, Innere Med 5, Med Klin, Homburg, Germany
[5] Krankenhaus Martha Maria Halle Dolau, Halle An Der Saale, Germany
[6] Lungenklin Lostau, Lostau, Germany
[7] Klinikum Chemnitz gGmbH, Dept Internal Med, Chemnitz, Germany
[8] Bruderkrankenhaus St Josef, Klin Hamatol & Onkol, Paderborn, Germany
[9] Klinikverbund Allgau, Clin Pneumol Thorac Oncol Sleep & Resp Med, Kempten, Germany
[10] Florence Nightingale Hosp, Dept Pulmonol Cardiol & Internal Intens Care, Dusseldorf, Germany
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs, Ingelheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V238
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) plus docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) plus chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial
    Grohe, Christian
    Wehler, Thomas
    Henschke, Sven
    Hammerschmidt, Stefan
    Aulmann, Christoph
    Krueger, Stefan
    Dittrich, Ina
    Schuette, Wolfgang
    von der Heyde, Eyck
    Hanson, Sven
    Bajorat, Joerg
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy
    Tang, Yu
    Wang, Wei
    Teng, Xiu-Zhi
    Shi, Lin
    TUMOR BIOLOGY, 2014, 35 (09) : 8945 - 8951
  • [23] Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
    Xie, Zhaoliang
    Liu, Jingru
    Wu, Min
    Wang, Xiaohan
    Lu, Yuhan
    Han, Chunyan
    Cong, Lei
    Li, Jisheng
    Meng, Xue
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [24] Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial
    Morelli, A. M.
    Migliorino, M. R.
    Morabito, A.
    Chiari, R.
    Grossi, F.
    Bordi, P.
    Di Costanzo, F.
    Delmonte, A.
    Romano, G.
    Misino, A.
    Scotti, V.
    Gregorc, V.
    Pisconti, S.
    Ceresoli, G. L.
    Del Conte, A.
    Colantonio, I.
    Ciuffreda, L.
    Capelletto, E.
    Stura, I.
    Novello, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Hammerschmidt, S.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Wehler, T.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S875 - S876
  • [26] Efficacy and safety of nintedanib plus docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
    Grohe, C.
    Hammerschmidt, S.
    Krueger, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Wehler, T.
    Atz, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 136 - 137
  • [27] COMPLETE ECONOMIC EVALUATION OF NINTEDANIB (VARGATEF®) PLUS DOCETAXEL AS A SECOND-LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN MEXICO
    Diaz Martinez, J.
    Soto, H.
    Baez-Revueltas, F. B.
    Herran, S.
    Gonzalez-Nieto, L. A.
    VALUE IN HEALTH, 2016, 19 (03) : A150 - A150
  • [28] Real World Results of Multiple Myeloma Patients - Low Mortality Rate from First-Line to Second-Line Treatment
    Keil, Felix
    Attalla, Petra
    Seebacher, Adelheid
    Burger, Sabine
    Koller, Elisabeth
    Sliwa, Thamer
    Laschan, Claudia
    Krauter, Andreas
    Pfeilstoecker, Michael
    Fillitz, Michael
    BLOOD, 2022, 140 : 12598 - 12599
  • [29] Real world results of multiple myeloma patients - low mortality rate from first-line to second-line treatment
    Keil, F.
    Attalla, P.
    Seebacher, A.
    Burger, S.
    Koller, E.
    Sliwa, T.
    Laschan, C.
    Krauter, A.
    Pfeilstoecker, M.
    List, A.
    Fillitz, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 180 - 181
  • [30] Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) plus docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
    Grohe, Christian
    Wehler, Thomas
    Henschke, Sven
    Dittrich, Ina
    Hammerschmidt, Stefan
    Aulmann, Christoph
    Dechow, Tobias
    Schiefer, Conrad
    Zander, Ingo
    Schuette, Wolfgang
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345